retatrutide triple hormone receptor agonist retatrutide Retatrutide: breakthrough… or still too early?, is an investigational triple-hormone (GLP-1 + GIP + glucagon) designed to go beyond current metabolic therapies by Retatrutide - Wikipedia

Clinical trial data have generated significant interest in retatrutide because of its substantial weight-loss results, including Phase 3 findings showing average body weight reductions of more than 30% at the highest studied dose over 80 weeks

These symptoms are usually mild to moderate and often improve after the first few weeks

Common spots include the inner arm, shoulder, stomach, or hip

Semaglutide, which was originally created to treat type 2 diabetes, belongs to the class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs)

Although retatrutide is not yet available outside of clinical trials, the factors that influence starting dose and titration speed are broadly consistent with those applied to similar licensed medicines

Staying hydrated, eating smaller meals, and avoiding fatty or spicy foods can minimize gastrointestinal discomfort during the adjustment period